

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

28 January 2019

Dear Shareholder,

Elections as to Means of Receipt and Language of Corporate Communications

Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, we are writing to seek your election in relation to the following matters regarding the corporate communication (“**Corporate Communication**”) of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) to be dispatched in the future.

Corporate Communication includes any document issued or to be issued by us for your information or action, including but not limited to: (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) a reply slip.

You may choose:

- (i) to read the Corporate Communication published on the Company’s website (“**Website Version**”) instead of receiving printed copies; or
- (ii) to receive a printed English version of the Corporate Communication only; or
- (iii) to receive a printed Chinese version of the Corporate Communication only; or
- (iv) to receive both the printed English and Chinese versions of the Corporate Communication.

For the purpose of environmental protection, we encourage you to select the Website Version. Even if you have chosen the Website Version, you reserve the right at any time by giving reasonable notice in writing to the H share registrar of the Company (“**H Share Registrar**”) to change your choice.

Please tick the appropriate box on the enclosed reply form (“**Reply Form**”) and sign and return it by post or by hand to the Company c/o the Company’s H Share Registrar, Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong, on or before 26 February 2019. If you post your Reply Form in Hong Kong, you may use the mailing label in the Reply Form and need not affix a stamp on the envelope when returning your Reply Form. Otherwise, please affix an appropriate stamp.

If the Company does not receive a duly completed and signed Reply Form from you (or another response from you indicating that you object to receiving the Website Version of Corporate Communications) on or before 26 February 2019, you will be deemed, until you inform the Company otherwise by reasonable notice in writing at the office of the H Share Registrar at the above address or by email to 1877-ecom@hk.tricorglobal.com, to have elected to receive all future Corporate Communications by Website Version instead of receiving them in printed form. In that event, when the Company makes a Corporate Communication, it will only send you a notification that the Corporate Communication has been made available on the Company’s website. The notification will be sent to you by email or by post at your address as it appears in the Company’s register of members maintained by the H Share Registrar.

You may at any time by reasonable notice in writing to the Company c/o the H Share Registrar at the above address or by email to 1877-ecom@hk.tricorglobal.com elect (i) to receive future Corporate Communications in printed form instead of by Website Version, or by Website Version instead of in printed form, or (ii) change the language in which you receive Corporate Communications in printed form. If you have elected (or are deemed to have elected) to receive Corporate Communications by Website Version and for any reason have difficulty in obtaining access to Corporate Communications on the Company’s website, the Company will upon request send the relevant Corporate Communications to you in printed form free of charge.

Please note that English and Chinese versions of all future Corporate Communications will be available (a) in printed form from the Company or the H Share Registrar on request and (b) on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and on the Company’s website at www.junshipharma.com.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2980 1333 during business hours (9:00 a.m. to 5:00 p.m. from Monday to Friday, excluding Hong Kong public holidays).

* For identification purpose only

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman